DGAP-News: Xenikos B.V. / Key word(s): Conference/Miscellaneous Xenikos B.V. to introduce immunotherapy T-Guard(TM) to potential pharmaceutical partners at BIO International Convention 2016 24.05.2016 / 14:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Xenikos B.V. to introduce immunotherapy T-Guard(TM) to potential pharmaceutical partners at BIO International Convention 2016 Nijmegen, the Netherlands, May 24, 2016 - Xenikos B.V., focused on the development of innovative immunotherapies for the treatment of patients suffering from serious immune diseases or rejection after transplantation, announced today that it will participate in the upcoming BIO International Convention (BIO), being held June 6-9, 2016 at the Moscone Center in San Francisco, CA, USA. At this conference, Xenikos will meet with pharmaceutical companies to discuss its product candidate, T-Guard(TM), for its lead indication acute graft versus host disease (GVHD). T-Guard(TM) is a combination of two toxin-loaded anti-T-cell antibodies being developed as a tool to safely and swiftly reset the body's immune system in T-cell mediated diseases, such as GVHD. T-Guard(TM) is currently in clinical phase 1/2 testing in Europe for the second-line treatment of steroid- resistant acute GVHD. Preliminary results from this study showed strong clinical responses and a doubling of the 6-months overall survival rate compared to a case series of historical controls. A clinical proof-of-concept study in this indication also showed that T-Guard(TM) appeared to be well tolerated with strong biological and clinical responses observed. Based on these promising results, the Company plans to initiate pivotal clinical studies mid 2017. Ypke van Oosterhout, Chief Executive Officer of Xenikos, said: "We are very excited to discuss our promising product candidate T-Guard(TM) for steroid- resistant acute GVHD with industry experts and key opinion leaders in the field of immunotherapy at this important event. We have seen a high level of interest in our Company and T-Guard(TM) by a number of pharmaceutical companies and look forward to evaluating further development opportunities, as we strongly believe that this innovative approach can help restore patients' health and save lives." Xenikos also said today that it has engaged U.S.-based strategic advisory firm Destum Partners, Inc. to support the Company with its partnering activities. Companies interested in meeting with Xenikos at BIO are asked to request a meeting through the BIO partnering online system or to contact Ypke van Oosterhout at y.vanoosterhout@xenikos.com. About T-Guard(TM) T-Guard(TM) is currently under development by Xenikos B.V. for the treatment of certain life-threatening immune conditions, such as transplant-related rejection, graft versus host disease (GVHD), acute solid-organ rejection and several severe autoimmune diseases. T-Guard(TM) consists of a combination of two toxin-loaded anti-T-cell antibodies and shows promise as a therapeutic tool for safely and swiftly resetting the body's immune system in T-cell-mediated diseases. Once injected into the body, T-Guard(TM) specifically identifies and eliminates adult T cells, with a strong preference for the activated ones. The particular combination of immunotoxins used to construct T-Guard(TM) was designed to provide a unique blend of synergistic efficacy, narrow specificity and multiple, gentle mechanisms of action. In preclinical testing, T-Guard(TM) was shown to be highly effective in killing activated T cells and to act through apoptosis (programmed cell death) mechanisms, which are associated with minimal side effects. T-Guard's targeted action is believed to leave patients less vulnerable to opportunistic infections when compared to historical controls of institutional standard of care. In a clinical proof- of-concept study, T-Guard(TM) appeared to be well tolerated with strong biological and clinical responses observed. T-Guard(TM) is currently in clinical phase 1/2 testing in Europe for the second-line treatment of steroid-resistant acute GVHD. The primary endpoint of the study is response rate at 28 days. Other endpoints include overall survival at 180 days; safety and tolerability are also being evaluated. Preliminary results from this study showed strong clinical responses and a doubling of the 6-months overall survival rate compared to historical controls with a well- manageable side effect profile without severe infusion reactions. T- Guard(TM) has been granted Orphan Drug Designation in both the EU and U.S. About Graft versus Host Disease (GVHD) Transplantation of allogeneic (donor-derived) blood stem cells is a widely accepted medical procedure to restore normal blood cell production (hematopoiesis) in patients treated for blood- or lymphatic cancers, or otherwise suffering from defective blood formation or immunity. Today, approximately 30,000 patients worldwide receive allogeneic stem cell transplants every year. Approximately 50% of all blood stem cell transplant patients develop acute GVHD, a complication where donor-derived T cells (immune cells) attack the normal tissues of the patient. Half of these patients do not respond adequately to standard first-line therapy and have a poor long-term prognosis with severe morbidity and high mortality rates. This number is expected to grow substantially as the number of patients receiving high-risk transplants from unrelated donors is expected to double in the next five years. As of today, there is no approved second-line treatment available. About Xenikos B.V. Xenikos B.V. is developing new, innovative immunotherapies to help restore patients' health and save lives. It is developing new therapies based on the action of conjugated antibodies that enables patients suffering from serious immune diseases or rejection after transplantation to reset their immune systems quickly and efficiently. Its lead product candidate T- GuardTM is currently being developed for the second-line treatment of steroid-resistant acute GVHD. Further information is available at www.xenikos.com. For further information, please contact: Xenikos B.V. Ypke van Oosterhout Chief Executive Officer Telephone: +31 24 3000100 Mobile: +31 6 11017611 Email: y.vanoosterhout@xenikos.com Additional contact information MC Services AG Dr. Solveigh Mähler Telephone: +49 211 529 252 19 E-mail: solveigh.maehler@mc-services.eu In the U.S.: Laurie Doyle Telephone: +1 339 832 0752 E-mail: laurie.doyle@mc-services.eu --------------------------------------------------------------------------- 24.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- 465919 24.05.2016
DGAP-News: Xenikos B.V. to introduce immunotherapy
Top 10 Most Recent News Articles
Laboratory Filtration Market Expands to $6.55B by 2031
A Niche Ready to Explode The laboratory filtration market isn't exactly the sort of thing that grabs headlines in the business section, but its growth is worth giving a second look. By 2031, this market's expected to hit $6.55 billion—up from $4.49 billion in 2026. If you think that's not impressive, chew on a 7.9% CAGR for the next few years. That's like watching your...
Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington
Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...
Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026
Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...
Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves
Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...
Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation
Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...
Continue Reading
Shareholder Alert: Investigation Looms Over GDYN
Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...
Continue Reading
Tenax Class Action: Investors Alley Fight for Redress
Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...
Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices
Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...
Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier
Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...
Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy
Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...
Continue ReadingTop 5 Most Recently Viewed Articles
Major Analyst Upgrades: Johnson & Johnson a Key Focus Today
Exciting Analyst Upgrades in the Stock Market The stock market is constantly evolving, and today's news shining a spotlight on several major companies is particularly noteworthy. Top Wall Street analysts have made significant changes to their outlooks for various stocks, resulting in several upgrades. Let’s take a closer look at these changes and what they might mean...
Continue Reading
Albany International Corp Facing Legal Scrutiny Over Misstatements
Albany International Corp Under Investigation Investors of Albany International Corp. are currently facing significant legal concerns that have given rise to an investigation. This inquiry is primarily centered on potential allegations of misleading statements issued by the company, which may have ultimately led to unexpected financial repercussions. As a well-known...
Continue Reading
Toncoin Experiences Notable Decline of Over 4% Today
Toncoin Price Analysis for Recent Days Recently, Toncoin experienced a notable decline, with its price dropping by 4.56% in just 24 hours, settling at $5.42. This downturn is quite different from its strong performance last week, during which Toncoin rose by an impressive 5.0%, increasing from $5.16 to the current price. Recent Price Movements and Volatility A closer look...
Continue Reading
AgriFORCE Unveils Innovative Strategy for Digital Infrastructure Growth
Revolutionizing the Digital Landscape: AgriFORCE's Strategy AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI), a key player in the digital infrastructure sector, has recently announced an innovative tri-pillar strategy designed to meet the growing global thirst for computational power. As demands for technology continue to rise, this comprehensive framework focuses on Bitcoin...
Continue Reading
Rethinking Infrastructure Finance: Unlocking Trillions
Cracking Open the Infrastructure Conundrum If you think America’s infrastructure is crumbling because of a lack of money, you’re only half right. The real hiccup lies in how we’ve rigged the system to access the cash pile. That’s what Anton Steshenko from the University of Maryland’s Smith School is shouting from the rooftops. According to him, it’s not a...
Continue Reading